Cost-effective analysis of transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis : A prospective multicenter study
Copyright © 2023 Elsevier Ltd. All rights reserved..
BACKGROUND: Transcatheter aortic valve replacement (TAVR) for severe symptomatic aortic stenosis (AS) does not benefit all patients. We performed a prospective multicenter study to investigate the cost-effectiveness of TAVR in a Japanese cohort.
METHODS AND RESULTS: We prospectively enrolled 110 symptomatic patients with severe AS who underwent TAVR from five institutions. The quality of life measurement (QOL) was performed for each patient before and at 6 months after TAVR. Patients without an improvement in QOL at 6 months after TAVR were defined as non-responders. Pre-TAVR higher QOL, higher clinical frailty scale predicted the non-responders. Three models, 1) conservative treatment for all patients strategy, 2) TAVR for all patients strategy, and 3) TAVR for a selected patient strategy who is expected to be a responder, were simulated. Lifetime cost-effectiveness was estimated using incremental cost-effectiveness ratio (ICER) and cost per quality-adjusted life-year (QALY) gained. In comparison to conservative therapy for all patients, ICER was estimated to be 5,765,800 yen/QALY for TAVR for all patients and 2,342,175 yen/QALY for TAVR for selected patient strategy patients, which is less than the commonly accepted ICER threshold of 5,000,000 yen/QALY.
CONCLUSIONS: TAVR for selected patient strategy model is more cost-effective than TAVR for all patient strategy without reducing QOL in the Japanese healthcare system. TAVR for selected patient strategy has potential benefit for optimizing the TAVR treatment in patients with high frailty and may direct our resources toward beneficial interventions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
Journal of cardiology - 83(2024), 3 vom: 27. Jan., Seite 169-176 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Amaki, Makoto [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cost effectiveness analysis |
|---|
| Anmerkungen: |
Date Completed 29.01.2024 Date Revised 29.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jjcc.2023.07.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360428827 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360428827 | ||
| 003 | DE-627 | ||
| 005 | 20240129231842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jjcc.2023.07.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1274.xml |
| 035 | |a (DE-627)NLM360428827 | ||
| 035 | |a (NLM)37543193 | ||
| 035 | |a (PII)S0914-5087(23)00184-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Amaki, Makoto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cost-effective analysis of transcatheter aortic valve replacement in patients with severe symptomatic aortic stenosis |b A prospective multicenter study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.01.2024 | ||
| 500 | |a Date Revised 29.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Transcatheter aortic valve replacement (TAVR) for severe symptomatic aortic stenosis (AS) does not benefit all patients. We performed a prospective multicenter study to investigate the cost-effectiveness of TAVR in a Japanese cohort | ||
| 520 | |a METHODS AND RESULTS: We prospectively enrolled 110 symptomatic patients with severe AS who underwent TAVR from five institutions. The quality of life measurement (QOL) was performed for each patient before and at 6 months after TAVR. Patients without an improvement in QOL at 6 months after TAVR were defined as non-responders. Pre-TAVR higher QOL, higher clinical frailty scale predicted the non-responders. Three models, 1) conservative treatment for all patients strategy, 2) TAVR for all patients strategy, and 3) TAVR for a selected patient strategy who is expected to be a responder, were simulated. Lifetime cost-effectiveness was estimated using incremental cost-effectiveness ratio (ICER) and cost per quality-adjusted life-year (QALY) gained. In comparison to conservative therapy for all patients, ICER was estimated to be 5,765,800 yen/QALY for TAVR for all patients and 2,342,175 yen/QALY for TAVR for selected patient strategy patients, which is less than the commonly accepted ICER threshold of 5,000,000 yen/QALY | ||
| 520 | |a CONCLUSIONS: TAVR for selected patient strategy model is more cost-effective than TAVR for all patient strategy without reducing QOL in the Japanese healthcare system. TAVR for selected patient strategy has potential benefit for optimizing the TAVR treatment in patients with high frailty and may direct our resources toward beneficial interventions | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cost effectiveness analysis | |
| 650 | 4 | |a Prospective multicenter study | |
| 650 | 4 | |a Transcatheter aortic valve replacement | |
| 700 | 1 | |a Moriwaki, Kensuke |e verfasserin |4 aut | |
| 700 | 1 | |a Nakai, Michikazu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamano, Tetsuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Okada, Atsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Kanzaki, Hideaki |e verfasserin |4 aut | |
| 700 | 1 | |a Izumo, Masaki |e verfasserin |4 aut | |
| 700 | 1 | |a Usuku, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Onishi, Tetsuari |e verfasserin |4 aut | |
| 700 | 1 | |a Nagai, Toshiyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Miyamoto, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Fujita, Tomoyuki |e verfasserin |4 aut | |
| 700 | 1 | |a Kawai, Hiroya |e verfasserin |4 aut | |
| 700 | 1 | |a Akashi, Yoshihiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tsujita, Kenichi |e verfasserin |4 aut | |
| 700 | 1 | |a Matoba, Satoaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kobayashi, Junjiro |e verfasserin |4 aut | |
| 700 | 1 | |a Izumi, Chisato |e verfasserin |4 aut | |
| 700 | 1 | |a Anzai, Toshihisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cardiology |d 1996 |g 83(2024), 3 vom: 27. Jan., Seite 169-176 |w (DE-627)NLM012655120 |x 1876-4738 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2024 |g number:3 |g day:27 |g month:01 |g pages:169-176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jjcc.2023.07.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2024 |e 3 |b 27 |c 01 |h 169-176 | ||